Prestige Consumer Healthcare (FRA:PBV) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PBV Prestige Consumer Healthcare Inc FRA:PBV
72 GF Score
Price €43.80
GF Value €59.76
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Prestige Consumer Healthcare Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Prestige Consumer Healthcare Quality Rank Related Terms

FRA:PBV
72GF Score
Prestige Consumer Healthcare Inc FRA:PBV
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Prestige Consumer Healthcare (FRA:PBV) Overvalued in 2026?

Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued. The current stock price of €43.80 is trading 26.7% below its estimated GF Value™ of €59.76. GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.

Key valuation signals for FRA:PBV:

  • Quality Rank:
  • GF Value™: €59.76 vs. price of €43.80 (26.7% below fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the FRA:PBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prestige Consumer Healthcare Business Description

Other Exchanges PBH:USA
Address 660 White Plains Road, Tarrytown, NY, USA, 10591
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
72GF Score

Get the complete analysis for FRA:PBV

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.80
Price
€59.76
GF Value